Article

Targeting both GD2 and B7-H3 using bispecific antibody improves tumor selectivity for GD2-positive tumors

2024-05-28

Abstract excerpt

<h4>Objectives</h4> Disialoganglioside 2 (GD2), overexpressed by cancers such as melanoma and neuroblastoma, is a tumor antigen for targeted therapy. The delivery of conventional IgG antibody technologies targeting GD2 is limited clinically by its co-expression on nerves that contributes to toxicity presenting as severe neuropathic pain. To improve the tumor selectivity of current GD2-targeting approaches, a next...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: c5f8ab6b-59e2-5e89-83c1-c2fd90586e9e
DOI: 10.1101/2024.05.23.595624

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Targeting both GD2 and B7-H3 using bispecific antibody improves tumor selectivity for GD2-positive tumorsDOI 10.1101/2024.05.23.595624Read

Anti-Cancer Immune Priming with Beta-Radioligand Therapy and Isoform-Selective Targeting of 4Ig-B7-H3Semantic proximity Read

Current Knowledge and Perspectives of Immunotherapies for NeuroblastomaSemantic proximity Read

Anti-GD2 antibody therapy alters the neuroblastoma tumor microenvironment and extends survival in <i>TH-MYCN</i> miceSemantic proximity Read

Alteration of Electrostatic Surface Potential Enhances Affinity and Tumor Killing Properties of Anti-ganglioside GD2 Monoclonal Antibody hu3F8.Semantic proximity Read

Immunoregulatory protein B7-H3 promotes growth and decreases sensitivity to therapy in metastatic melanoma cells.Semantic proximity Read

ITC-6102RO, A Novel B7-H3 Antibody-Drug Conjugate, Exhibits Potent Therapeutic Effects against B7-H3 Expressing Solid TumorsSemantic proximity Read

In silico Driven Redesign of a Clinically Relevant Antibody for the Treatment of GD2 Positive TumorsSemantic proximity Read

An Optimized GD2-Targeting Retroviral Cassette for More Potent and Safer Cellular Therapy of Neuroblastoma and Other CancersSemantic proximity Read

GD2-specific Chimeric Antigen Receptor-modified T Cells for the treatment of Refractory and/or Recurrent Neuroblastoma in Pediatric PatientsSemantic proximity Read

Neuroblastoma GD2 Expression and Computational Analysis of Aptamer-Based Bioaffinity TargetingSemantic proximity Read

Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas.Semantic proximity Read

Autologous Anti-GD2 CAR T Cells Efficiently Target Primary Human GlioblastomaSemantic proximity Read